Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151149 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
A Phase 4 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 4
- Development phase
- 143
- Enrollment target
NCT02151149 is a Phase 4 study that has completed, run by Celgene. The registered enrollment target is 143 participants.
The verdict
NCT02151149, a Phase 4 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 143 participants
- Enrollment target
Study Summary
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Interventions
- DRUG Carboplatin
- DRUG nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-06-09 |
| Est. Completion | 2017-07-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02151149
The ClinicalTrials.gov registry entry for NCT02151149 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT02151149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02151149 about?
NCT02151149 is a clinical study titled "Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly". Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
What is the current status of trial NCT02151149?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 143 participants. The study started on 2014-06-09. Estimated completion is 2017-07-14.
What interventions are being tested in trial NCT02151149?
The interventions under investigation include: Carboplatin (DRUG), nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02151149?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.